RHTLaw Taylor Wessing advised Bioxis Pharmaceuticals on funding by Chinese medical technology company OHMK (Tianjin) Medical Technology Co., Ltd

RHTLaw Taylor Wessing advised Bioxis Pharmaceuticals on funding by Chinese medical technology company OHMK (Tianjin) Medical Technology Co., Ltd

RHTLaw Taylor Wessing advised French biotechnology company, Bioxis Pharmaceuticals, on an investment from a Chinese medical technology company, OHMK (Tianjin) Medical Technology Co., Ltd. of about €4 million in shares, and in warrants convertible into shares of a value of about €8 million.

Bioxis Pharmaceuticals specialises in research, development, production and commercialisation of innovative regenerative products in the field of aesthetic dermatology. Its notable products are MTI-12, the first monophasic tissular inductor, based on Chitosan matrix technology, with the power to regenerate neo-tissues and collagen, as well as Cytosial, a monophasic hyaluronic acid dermal filler based on hyaluronic cross linked Velvet technology, for the treatment of medical conditions such as HIV associated lipoatrophy. The equity capital raising will finance part of the development of Bioxis Pharmaceutical’s products and technology, and its completion of clinical trials.

The Chinese investor has previously invested in Bioxis Pharmaceuticals and has entered into a commercial agreement to distribute its products in China, Hong Kong, Macau and Taiwan. This investment is a strategic move for both Bioxis Pharmaceuticals and OHMK (Tianjin) Medical Technology Co., Ltd in accelerating the growth of their businesses into the Chinese and European markets respectively.

Deputy Head of Corporate Practice (Foreign Lawyer) Erwan Barre led the project.